

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. EVANS
Title: SELECTIVE DIPEPTIDE INHIBITORS OF
KALLIKREIN
Int'l Appl. No.: PCT/GB03/00908
Int'l Filing Date: March 4, 2003
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

The references entitled "Involvement of Tissue Kallikrein but not Plasma Kallikrein in the Development of Symptoms Mediated by Endogenous Kinins in Acute Pancreatitis in Rats" and "A Synthetic Tissue Kallikrein Inhibitor Suppresses Cancer Cell Invasiveness", listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding International application. Copies of these documents are not being provided since copies should have been

provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Copies of all other documents cited in the attached PTO/SB/08 are attached.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 2 September 2004

By S. A. Bent

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 3, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Unassigned 10/506535
				Filing Date	09/03/2004
				First Named Inventor	David M. EVANS
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	052209-0124
Sheet	1	of	2		

1U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1		WO 95/07291		FERRING BV	3/16/1995		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A2	International Search Report	
	A3	T. Griesbacher et al., "Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats", British Journal of Pharmacology, vol. 137, no. 5, November 2002, pp. 692-700, XP002252617, Basingstoke, Hants., GB ISSN: 0007-1188 the whole document.	
	A4	W.C. Wolf et al., "A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness", American Journal of Pathology, vol. 159, no. 5, November 2001, pp. 1797-1805, XP002252618, Philadelphia PA, US, ISSN: 0002-9440 the whole document.	
	A5	K.D. BHOOLA et al., "Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases", Pharmacological Reviews, Vol. 44, No. 1, 1992, pp. 1-80.	
	A6	D. Michael EVANS et al., "Selective Inhibitors of Plasma Kallikrein", Immunopharmacology, 32 (1996) pp. 115-116.	
	A7	D. Michael EVANS et al., "Synthetic Inhibitors of Human Tissue Kallikrein", Immunopharmacology, 32 (1996), pp. 117-118.	
	A8	J. STÜRZEBECHER et al., "Novel Plasma Kallikrein Inhibitors of the Benzamidine Type", Brazilian J Med Biol Res (1994) 27, pp. 1929-1934.	
	A9	Naoki TENO et al., "Development of Active Center-Directed Plasmin and Plasma Kallikrein Inhibitors and Studies on the Structure-Inhibitory Activity Relationship", Chem. Pharma. Bull. 41(6) pp. 1079-1090 (1993).	
	A10	Y. FUJIMORI et al., "Effects of a Highly Selective Plasma Kallikrein Inhibitor on Collagen-Induced Arthritis in Mice", Agents Actions, 39, (1993), pp. 42-48.	
	A11	S. OKAMOTO et al., "A Finding of Highly Selective Synthetic Inhibitor of Plasma Kallikrein: It's Action to Bradykinin Generation, Intrinsic Coagulation and Experimental DIC", Recent Progress on Kinins, 1992, pp. 198-204.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: September 3, 2004

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	Unassigned	10/506535
Filing Date	09/03/2004	
First Named Inventor	David M. EVANS	
Group Art Unit	Unassigned	
Examiner Name	Unassigned	
Attorney Docket Number	052209-0124	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A12	Antoni STADNICKI MD et al., "Selective Plasma Kallikrein Inhibitor Attenuates Acute Intestinal Inflammation in Lewis Rat", Digestive Diseases and Sciences, Vol. 41, No. 5, May 1996, pp. 912-920.	
	A13	J. Sueras-Diaz et al., "Cleavage of human Kininogen fragments at Met-Kys by human tissue kallikrein", Brazilian J Med Biol Res (1994) 27: 1935-1942.	
	A14	H.T. Johansen et al., "Assay of Kallikrein Inhibitors and Leves of Acetone-Activated Kallikrein in Plasma Specimens from Reactors to Dextran or to Contrast Media", INT. J. TISS. REAC. VIII(3), pp. 185-192, (1986).	
	A15	Deepak K. SHORI et al., "New Specific Assays for Tonin and Tissue Kallikrein Activities in Rat Submandibular Glands", Biochemical Pharmacology, Vol. 43, No. 6, pp. 1209-1217, 1992.	
	A16	Jörg STÜRZEBECKER et al., "Inhibition of Human Mast Cell Tryptase by Benzamidine Derivatives", Biol. Chem. Hoppe-Seyler, Vol. 373, pp. 1025-1030, October 1992.	
	A17	M. DIXON, "The Determination of Enzyme Inhibitor Constants", Biochemical Laboratory, University of Cambridge, Vol. 55, pp. 170-171, 1953.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.